NCT06638931 2026-04-15ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Recruiting28 enrolled
NCT02834013 2026-04-13Nivolumab and Ipilimumab in Treating Patients With Rare TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting818 enrolled
NCT03860272 2026-03-30Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerAgenus Inc.Phase 1 Active not recruiting499 enrolled